SCHEMBL1337784

SCHEMBL1337784

CCCCOc1cccc(-c2c(F)cc(NC(=O)c3ccccc3C(=O)O)cc2F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 5/20 0.55
DHODH Q02127 3/20 0.51
NR4A2 P43354 1/20 0.51
THRB P10828 1/20 0.49
HTT P42858 1/20 0.48
RECQL P46063 1/20 0.48
FABP1 P07148 1/20 0.48
MAPK1 P28482 1/20 0.47
GFER P55789 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
PPARA Q07869 1/20 0.46
GPR35 Q9HC97 1/20 0.46
AKR1C2 P52895 1/20 0.46
AKR1C1 Q04828 1/20 0.46
GAA P10253 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PTPN11 Q06124 2/20 0.46
ALDH1A1 P00352 1/20 0.46
MCL1 Q07820 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337732 0.88 NR1H4 (0.56) NR1H4DHODHNR4A2THRBHTT
SCHEMBL1335633 0.86 DHODH (0.55) NR1H4DHODHNR4A2THRBAKR1C2
SCHEMBL1335695 0.85 NR1H4 (0.62) NR1H4DHODHNR4A2THRBHTT
SCHEMBL1335438 0.84 DHODH (0.66) NR1H4DHODHNR4A2AKR1C2AKR1C1
SCHEMBL1337478 0.84 DHODH (0.71) NR1H4DHODHNR4A2AKR1C2AKR1C1
SCHEMBL2595923 0.81 DHODH (0.52) NR1H4DHODHNR4A2AKR1C2AKR1C1
SCHEMBL12129672 0.81 DHODH (0.58) NR1H4DHODHNR4A2HTTRECQL
SCHEMBL29709148 0.81 DHODH (0.58) NR1H4DHODHNR4A2HTTRECQL
SCHEMBL1335530 0.80 FABP1 (0.57) NR1H4DHODHHTTFABP1MAPK1
SCHEMBL1337021 0.79 DHODH (0.67) DHODHNR4A2HTTFABP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 EP claimed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US claimed
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 EP disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR NR1H4 1217/4885DHODH 1/4885NR4A2 1697/4885
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR NR1H4 1217/4885DHODH 1/4885NR4A2 1697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.